---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-035943"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:36:21.998052+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman

## Summary
- Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.
- Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).
- David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.
- Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance.

## SEC filing metadata
- accession: 0000950170-25-035943
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/itrm-20250307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-035943
- JSON: https://secwatch.observer/filing/0000950170-25-035943.json
- Plain text: https://secwatch.observer/filing/0000950170-25-035943.txt

## Source-grounded claims
- claim_id: aca580e0fc
  claim: Joseph J. Whalen was appointed as Class III Director at Iterum Therapeutics plc.
  evidence_excerpt: approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm
- claim_id: dd3bddcdb1
  claim: David Kelly was appointed as Chairman of the Board at Iterum Therapeutics plc.
  evidence_excerpt: the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.